Debut Plus

BSE · 531592

Genpharmasec Limited

₹0.97
₹54 Cr market cap
P/E
34.33
EPS
₹0
Book value
₹1.2
ROE
241.95%
ROCE
2.18%
Debt / equity
0.31

Revenue & net profit by period

Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.

035.7771.55107143Mar 25Mar 25Jun 25Sep 25Dec 25Mar 26Mar 26Jun 26
Revenue (₹ Cr) Net profit (₹ Cr)

Latest period: revenue ₹45 Cr with net profit ₹2 Cr — a 3.51% net margin, versus 4.49% the period before.

Shareholding

As of 2026-09-30

32.06%
promoter holding
  • Promoter32.06%
  • Public67.94%

99,856 shareholders on record

Promoter holding trend

Each disclosed period, oldest to newest

29.98%32.06%Dec 24Sep 26

52-week position

Where the current price sits in its yearly band

₹0.75₹0.97₹1.8

The band spans 2.4× from low to high.

Risk flags

Derived from disclosed data

No flags raised by the data.

Peer comparison

Trading · ranked #267 of 689 by market cap · medians across 50 industry peers

P/E
34.33vs 34.91 peer med
P/B
0.81vs 4.94 peer med
ROE %
241.95vs 13.34 peer med
Margin %
-14.64vs 4.59 peer med
CompanyMkt capP/EP/BROEMargin
Adani Enterprises Limited₹3,35,624 Cr130.383.433.66%4.59%
Avenue Supermarts Limited₹2,04,427 Cr65.597.8311.94%4.2%
Trent Ltd.₹1,55,379 Cr84.9822.2524.62%8.64%
FSN E-Commerce Ventures Ltd.₹98,116 Cr368.2868.1213.87%2.41%
Aditya Infotech Limited₹48,793 Cr102.2414.4419.61%9.77%
Aegis Logistics Limited₹41,520 Cr31.166.2320.01%14.99%
Vishal Mega Mart Limited₹41,203 Cr45.815.2211.37%6.45%
Premier Energies Limited₹38,368 Cr23.048.9135.05%19.67%
Redington Limited₹27,472 Cr15.272.714.67%1.33%
Honasa Consumer Limited₹14,707 Cr58.2810.3814.16%9.75%
Genpharmasec Limited(this company)₹54 Cr34.330.812.42%-14.64%

AI analysis

AI-generated · google/gemini-2.5-flash

Genpharmasec Limited does not have specified business activities. The company reported a market capitalization of Rs 58 Cr. Its revenue stood at Rs 36.78 Cr with a profit margin of 31.4%.

Positives

  • +The company has a low debt-to-equity ratio of 0.07.
  • +The Return on Equity (ROE) is significantly high at 242%.
  • +The company recorded a profit margin of 31.4%.

Negatives

  • −Promoter holding is relatively low at 29.9792%.
  • −Return on Capital Employed (ROCE) is low at 2.1844%.
  • −The company experienced negative net profit in December 2025 (-Rs 0.83 Cr) and September 2025 (-Rs 1.18 Cr).

Financial Performance

For the fiscal year ending March 2025, Genpharmasec Limited reported revenue of Rs 36.784 Cr and a net profit of Rs 1.2312 Cr. Quarterly revenue for March 2026 was Rs 55.43 Cr, with a net profit of Rs 1.23 Cr. Over the past four quarters, revenue fluctuated, with a high of Rs 55.43 Cr in March 2026 and a low of Rs 8.48 Cr in December 2024.

Profitability & Returns

Genpharmasec Limited achieved a profit margin of 31.4%. The company's Return on Capital Employed (ROCE) was 2.1844% and Return on Equity (ROE) was 242%. Earnings per share (EPS) for the fiscal year ending March 2025 was Rs 0.02. The PE ratio for the company is 35.

Balance Sheet

The company's debt-to-equity ratio is 0.07, indicating a low level of debt relative to its equity. The book value per share is Rs 1.2.

Ownership & Pledges

As of June 30, 2026, promoter holding in Genpharmasec Limited stood at 29.9792%, while public shareholding was 70.0208%. There is no pledged promoter holding. The number of shareholders was 101,134.

Regulatory & Surveillance

There is no information available regarding any surveillance measures on Genpharmasec Limited.

Data as of — price: 2026-10-29 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.

How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.

Back to Genpharmasec Limitedshare price & fundamentals